Fluoroquinolones - Established Products Drive Market Growth

Introduction

The quinolones are the fastest growing antibacterial class in terms of global revenue, increasingly being used in both the hospital and community sectors to treat a broad range of infections. However, the forthcoming US patent expiry of Bayer's blockbuster Cipro, is set to change the dynamics of this sector while novel compounds are increasingly favored in the light of drug resistance. 

Scope

In depth analysis of the fluoroquinolone class as a whole and detailed profiles of leading class members. 

Global and regional (US and EU) sales for leading quinolones in 2001 and 2002 are presented along with projections for future performance up to 2008. 

Market segmentations by key sites of infection based on extensive expert consultation, are provided for 2002 and 2008.  

Report Highlights

Fluoroquinolone sales are expected to remain relatively constant to 2011 (CAGR 2003-2010 = -0.3%). Growth during this period will be driven by increased use of quinolones in the treatment of less severe respiratory tract infections in the community sector and aggressive life-cycle management of Levaquin and Avelox; 

The fluoroquinolone market is heavily dominated by ciprofloxacin and levofloxacin, which together command 65% ($3.3 billion) of global sales. The broad spectrum of pathogen activity exhibited by these compounds, alongside their wide range of available formulations, creates significant challenges for companies looking to introduce novel products 

Although ciprofloxacin’s key strengths lie in the treatment of urinary tract infections (UTIs), the majority (>60%) of its sales are derived from the treatment of infections of the respiratory tract (RTIs. Datamonitor believes that effective penetration of the RTI sector remains key to product success 

Reasons to Purchase

Assess leading fluoroquinolone compounds and identify key success factors within this sector; 

Understand the drivers and limits to fluoroquinolone use and predict future performance of these compounds.  

Benchmark pipeline fluoroquinolones against currently marketed products and assess future market potential.

January 2004, 103 pages 

Publisher: Datamonitor Infectious Diseases Reports 2004 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Infectious_Diseases_Reports_2004.html#a555